Skip to main content

Table 3 FOIAS of phases 1–3 and PVM (PrimaVistaMode) in FOI at baseline and after 12 months (n = 35 for FOIAS parameters

From: Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period

 

Month of visit 0 (V0)*

Month of visit 12 (V12)*

Difference between V12 and V0*

p value (Wilcoxon signed rank test)

Phase 1

5 (1.04;26)

(0;70.91)

1 (0;4)

(0;32)

−3 (− 17;0)

(−69.91;12)

0.00445 (sig.)

Phase 2

16 (10.5;25)

(1;40)

16 (9.5;24)

(2;43)

2 (−4.5;6.81)

(− 18;18)

0.6004

Phase 3

1 (0;2.5)

(0;15)

1 (0;4)

(0;10)

0 (− 1;1.5)

(− 12;9)

0.5451

PVM

9 (4.5;13)

(0;24)

9 (3.5;14)

(0;26)

−1 (−4;4)

(− 15;14)

0.7461

  1. Phases 1–3 and PVM (PrimaVistaMode) of FOI at baseline and after 12 months (n = 35): FOIAS fluorescence optical imaging activity score; *median (1. quartile; 3. quartile); (min; max); significance level = 0.05
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us